Lyell Wealth Management LP Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lyell Wealth Management LP lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,781 shares of the medical research company’s stock after buying an additional 1,013 shares during the quarter. Thermo Fisher Scientific makes up 1.4% of Lyell Wealth Management LP’s holdings, making the stock its 17th largest holding. Lyell Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $15,317,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $25,000. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $30,000. IMA Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $35,000. Navigoe LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $37,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO stock opened at $477.01 on Thursday. The company’s 50-day moving average price is $418.15 and its 200-day moving average price is $468.92. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $180.07 billion, a price-to-earnings ratio of 27.59, a PEG ratio of 2.58 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.36%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Raymond James Financial restated an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Argus reduced their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Finally, HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $593.00.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.